The Classification for Adverse Events in GastRointEstinal Endoscopy (AGREE): Three-Year Evaluation and Additional Recommendations
Endoscopy International Open · 13.10.2026 · 14 (CP)
DOI: 10.1055/a-2965-6729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 13.10.2026. Verfasst von Querijn N E van Bokhorst und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and HepatologyAmsterdam UMCAmsterdamthe Netherlands. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
In 2021, a novel classification for gastrointestinal endoscopy-related adverse events (AEs) was introduced: the AGREE classification. This classification was developed to minimize subjectivity in AE assessment and facilitate more robust comparisons of endoscopic and surgical procedures. We conducted a comprehensive review of the classification three years after its introduction.
Methods
A citation analysis of the original AGREE publication was performed through March, 2025. Identified articles were reviewed to evaluate the classification’s adoption, application, use for intra- and interdisciplinary comparisons, and comparability with other classifications. Accuracy of AE classifications was assessed based on review of unique scenarios reported across identified articles. Variability in the definition and reporting of AEs across studies was evaluated.
Results
In total, 167 unique articles, involving 33 countries across 5 continents, were identified. A notable year-over-year increase was observed. Available studies illustrated feasibility of the AGREE to facilitate both intra- and interdisciplinary comparisons, alongside significant correlations between AGREE-based AE severity assessments and assessments using other classifications. Accuracy of gradings was estimated at 85%. Misclassifications mostly involved overclassification of events without sequelae for the patient. Inconsistencies in grading, definition, and reporting of AEs were identified. Findings were used to establish recommendations for grading specific (challenging) AE scenarios and develop a checklist to support more standardized AE reporting.
Conclusions
A gradual increase in the annual citations of the AGREE classification was observed, suggesting growing awareness and academic interest. The recommendations provided could support more consistent grading, definition, and reporting of AEs, thereby improving opportunities for endoscopy quality evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and HepatologyAmsterdam UMCAmsterdamthe Netherlands.
- Amsterdam Gastroenterology Endocrinology MetabolismAmsterdamthe Netherlands.
- Cancer Center AmsterdamAmsterdamthe Netherlands.
- Department of Gastroenterology and HepatologyRijnstate HospitalArnhemthe Netherlands.
- Department of Gastroenterology and HepatologyWaikato HospitalHamiltonNew Zealand.
ORCID-Profile: Querijn N E van Bokhorst, Evelien Dekker
Zitieren
APA
van Bokhorst, Q. N. E., Bierma, H., Nass, K. J., Dekker, E., van der Vlugt, M., & Fockens, P. (2026). The Classification for Adverse Events in GastRointEstinal Endoscopy (AGREE): Three-Year Evaluation and Additional Recommendations. Endoscopy International Open, 14(CP). https://doi.org/10.1055/a-2965-6729
Vancouver
van Bokhorst QNE, Bierma H, Nass KJ, Dekker E, van der Vlugt M, Fockens P. The Classification for Adverse Events in GastRointEstinal Endoscopy (AGREE): Three-Year Evaluation and Additional Recommendations. Endoscopy International Open. 2026;14(CP). doi:10.1055/a-2965-6729
BibTeX
@article{vanBokhorst2026,
author = {van Bokhorst, Querijn N E and Bierma, Hessel and Nass, Karlijn J and Dekker, Evelien and van der Vlugt, Manon and Fockens, Paul},
title = {The Classification for Adverse Events in GastRointEstinal Endoscopy (AGREE): Three-Year Evaluation and Additional Recommendations},
journal = {Endoscopy International Open},
year = {2026},
volume = {14},
number = {CP},
doi = {10.1055/a-2965-6729}
}
EUVIMED